# Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients

> **NCT06015061** · — · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Pheochromocytoma, Metastatic
- Ultrasonography
- Paraganglioma, Malignant
- Pheochromocytoma Malignant

## Interventions

- **DIAGNOSTIC_TEST:** Contrast-enhanced ultrasound(CEUS)

## Key facts

- **NCT ID:** NCT06015061
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015061, "Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06015061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*